Drug Type Small molecule drug |
Synonyms Compound 31(National Center for Advancing Translational Sciences) |
Target |
Mechanism FLT3 inhibitors(Tyrosine-protein kinase receptor FLT3 inhibitors), IRAK1 antagonists(Interleukin-1 receptor-associated kinase 1 antagonists), IRAK4 inhibitors(Interleukin-1 receptor-associated kinase 4 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC21H26FN5O2 |
InChIKeySPZWEDSSAIAPRC-HOCLYGCPSA-N |
CAS Registry2760328-82-1 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Myeloid Leukemia | Preclinical | US | 23 Oct 2024 |